555 related articles for article (PubMed ID: 30467877)
1. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
3. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
7. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
[TBL] [Abstract][Full Text] [Related]
8. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Sirinawasatien A; Techasirioangkun T
PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
[TBL] [Abstract][Full Text] [Related]
13. Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.
Yanny B; Saab S; Durazo F; Latt N; Mitry A; Mikhail MM; Hanna RM; Aziz A; Sahota A
Dig Dis Sci; 2018 Dec; 63(12):3480-3486. PubMed ID: 30259281
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS; Shahoumian TA; Loomis TP; Backus LI
J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
[TBL] [Abstract][Full Text] [Related]
16. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Shin HP; Burman B; Kozarek RA; Zeigler A; Wang C; Lee H; Zehr T; Edwards AM; Siddique A
Gut Liver; 2017 Sep; 11(5):711-720. PubMed ID: 28651301
[TBL] [Abstract][Full Text] [Related]
17. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.
Babatin MA; AlGhamdi AS; Assiri AM; AlBiladi H; AlOthmani HS; Mogharbel MH; Mahallawi W; Asselah T; Sanai FM
Saudi J Gastroenterol; 2019; 25(1):55-60. PubMed ID: 30117490
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
19. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
